Gilead is finally showcasing another pipeline for hepatitis C virus infection.

The pharmaceutical industry source reported Gilead Science Korea has submitted an application for the South Korean health authority’s approval on a pan-genotype hepatitis C virus (HCV) infection treatment Epclusa (sofosbuvir/velpatasvir) to be used on an adult patient with chronic HCV infection, regardless of liver cirrhosis.

Epclusa is a fixed-dose combination drug consisting of 400 mg of Sovaldi (sofosbuvir), authorized by the U.S. Food and Drug Administration (FDA) in 2013, and 100 mg of a nonstructural protein 5A (NS5A) inhibitor velpatasvir. The combination drug can be administered once-daily in combin